ATE428442T1 - Immuntherapeutikum für die kombinierte behandlung von tuberkulose mit anderen pharmazeutika - Google Patents

Immuntherapeutikum für die kombinierte behandlung von tuberkulose mit anderen pharmazeutika

Info

Publication number
ATE428442T1
ATE428442T1 AT04791401T AT04791401T ATE428442T1 AT E428442 T1 ATE428442 T1 AT E428442T1 AT 04791401 T AT04791401 T AT 04791401T AT 04791401 T AT04791401 T AT 04791401T AT E428442 T1 ATE428442 T1 AT E428442T1
Authority
AT
Austria
Prior art keywords
tuberculosis
combined treatment
immunotherapeutic
pharmaceuticals
agent
Prior art date
Application number
AT04791401T
Other languages
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Application granted granted Critical
Publication of ATE428442T1 publication Critical patent/ATE428442T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04791401T 2003-10-31 2004-10-29 Immuntherapeutikum für die kombinierte behandlung von tuberkulose mit anderen pharmazeutika ATE428442T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
PCT/ES2004/000482 WO2005042013A1 (es) 2003-10-31 2004-10-29 Agente immunoterápico útil para el tratamento combinado de la tuberculosis en associación con otros fármacos

Publications (1)

Publication Number Publication Date
ATE428442T1 true ATE428442T1 (de) 2009-05-15

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04791401T ATE428442T1 (de) 2003-10-31 2004-10-29 Immuntherapeutikum für die kombinierte behandlung von tuberkulose mit anderen pharmazeutika

Country Status (21)

Country Link
US (1) US8246944B2 (de)
EP (1) EP1690549B1 (de)
JP (1) JP4998988B2 (de)
KR (1) KR101146469B1 (de)
CN (1) CN100490894C (de)
AT (1) ATE428442T1 (de)
AU (1) AU2004285305B2 (de)
BR (1) BRPI0415695B8 (de)
CA (1) CA2543659C (de)
DE (1) DE602004020663D1 (de)
DK (1) DK1690549T3 (de)
ES (2) ES2231037B1 (de)
HK (1) HK1098362A1 (de)
IL (1) IL175030A (de)
MA (1) MA28121A1 (de)
NZ (1) NZ546715A (de)
PL (1) PL1690549T3 (de)
PT (1) PT1690549E (de)
RU (1) RU2341287C2 (de)
WO (1) WO2005042013A1 (de)
ZA (1) ZA200604234B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
CA2652475A1 (en) * 2006-05-12 2007-11-22 National University Corporation Hokkaido University Liposome having lipid membrane containing bacterial cell component
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
SI2661253T1 (sl) * 2011-01-04 2017-07-31 Archivel Farma, Sl Liposomska formulacija, ustrezna za zdravljenje ali preprečevanje tuberkuloze
EP2471511A1 (de) 2011-01-04 2012-07-04 Archivel Farma, SL Zur Behandlung oder Vorbeugung von Tuberkulose geeignete Liposomformulierung
WO2013104943A1 (en) 2012-01-12 2013-07-18 Archivel Farma, S.L. Mtb-c vaccine against asthma
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
WO2023062066A1 (en) 2021-10-14 2023-04-20 Archivel Farma, S.L. Liposome formulations for treatment of active tuberculosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
CA2346218A1 (en) * 1998-10-08 2000-04-20 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
EP1351699A4 (de) * 2000-12-08 2006-07-05 Ying Dr Zhang Verfahren zur verbesserten diagnose und behandlung von mykobakterieninfektionen
CA2433069C (en) * 2001-01-08 2010-03-30 Frederick D. Quinn Latent human tuberculosis model, diagnostic antigens, and methods of use
EP1379529A2 (de) * 2001-03-16 2004-01-14 Sarawak Medichem Pharmaceuticals, Inc. Pyranocoumarin verbindungen als neue pharmakophore mit anti-tb activität
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003018053A1 (en) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine against mycobacterial-induced diseases
BR0307262A (pt) 2002-01-29 2006-12-19 Bakulesh Mafatlal Khamar método de prover profilaxia para tuberculose em indivìduos hiv positivos
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
MA28121A1 (fr) 2006-08-01
US20070269501A1 (en) 2007-11-22
CA2543659A1 (en) 2005-05-12
BRPI0415695B8 (pt) 2021-05-25
BRPI0415695B1 (pt) 2019-09-10
BRPI0415695A8 (pt) 2019-01-15
DK1690549T3 (da) 2009-08-17
AU2004285305B2 (en) 2009-11-12
JP4998988B2 (ja) 2012-08-15
RU2341287C2 (ru) 2008-12-20
EP1690549A1 (de) 2006-08-16
ES2231037A1 (es) 2005-05-01
AU2004285305A1 (en) 2005-05-12
HK1098362A1 (en) 2007-07-20
KR101146469B1 (ko) 2012-05-21
ES2325835T3 (es) 2009-09-21
CA2543659C (en) 2012-04-17
CN100490894C (zh) 2009-05-27
BRPI0415695A (pt) 2006-12-26
US8246944B2 (en) 2012-08-21
CN1874785A (zh) 2006-12-06
DE602004020663D1 (de) 2009-05-28
RU2006118795A (ru) 2007-12-10
ES2231037B1 (es) 2005-12-16
JP2007509910A (ja) 2007-04-19
IL175030A (en) 2012-02-29
PT1690549E (pt) 2009-07-20
WO2005042013A1 (es) 2005-05-12
ZA200604234B (en) 2007-11-28
EP1690549B1 (de) 2009-04-15
PL1690549T3 (pl) 2010-01-29
NZ546715A (en) 2008-05-30
KR20060126963A (ko) 2006-12-11
IL175030A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
HK1098362A1 (en) Immunotherapic agent which is used for the combined treatment of tuberculosis togetheir with other pharmaceuticals
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
SE0301700D0 (sv) Novel compounds
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
EP1783126A3 (de) N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
PT1506185E (pt) Compostos novos e sua utilizacao
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE60226652D1 (de) Vorrichtung und verfahren zur sofortigen herstellung einer individuellen dosierungscharge
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
BRPI0518790A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
MXPA04005552A (es) Analogos de vitamina d.
ATE424896T1 (de) Entpigmentisierende bzw. aufhellende kosmetikzusammensetzung, die mindestens ein oxazolin als wirkstoff umfasst
EP1603595A4 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE440826T1 (de) Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
ATE259784T1 (de) Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2005035746A3 (en) Medical use of tbk-1 or of inhibitors thereof
DE602006002328D1 (de) Polysubstituierte 1,1-pyridinyloxycyclopropanamine Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
WO2003096987A9 (en) Methods of use and compositions for the diagnosis and treatment of infectious disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties